Back to discover
Drug

Arsenic

In clinical development
Emerging researchEarly-to-mid development

Also known as As - Arsenic.

1
Research papers
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Arsenic
Aliases & brands
As - Arsenic
RxNorm CUI
1111
ChEMBL ID
CHEMBL1231052
UNII
N712M78A8G

Clinical trials

1 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme
CLINICALTRIALS.GOV · LIVE REGISTRY
1
registered trials across all phases
LATEST COMPLETION 2010
1
Completed
PHASE DISTRIBUTIONn = 1
Phase 1 / 21

Recent completions

Trials that read out recently, adding to the completed evidence base.

Research activity

1 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Most influential

Arsenic: A Global Environmental Challenge.

Annual review of pharmacology and toxicology · 2021 · 176 cites
Recent papers

Arsenic: A Global Environmental Challenge.

Annual review of pharmacology and toxicology · 2021 · 176 cites
Major research themes2
Arsenic1Neoplasms1
Journals, researchers & institutions
Top journals
  • Annual review of pharmacology and toxicology1
Leading researchers
  • Chen QY1
  • Costa M1
Leading institutions
free-text, unnormalised
  • New York University School of Medicine1
  • School of Basic Medical Sciences1
References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
  • Europe PMC — research literature
  • ClinicalTrials.gov — clinical trials